Precision BioSciences Inc PBGENE-HBV Hepatitis B Investor Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Maury Raycroft - Jefferies - Analyst : Hi, congrats on the progress and thanks for taking my questions. Maybe I'll just start with 1, just for exploratory biomarkers. Will you assess immune function at baseline and posttreatment in patients to see if by reducing the S-antigen, you're enabling some immune system restoration that could give you additional confidence about stopping nucs?

Question: Maury Raycroft - Jefferies - Analyst : Sure. Yes, I'll do one more quick one. So just based on the last question in response, it sounds like in the models, there's a higher total amount of cccDNA versus what you see in infected humans. But I'm just wondering if in infected humans there could be reservoirs of cccDNA. And this could -- this variability could affect how PBGENE-HBV works. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Maury Raycroft - Jefferies - Analyst : Okay. Thank you very much for taking my questions.

Question: Soumit Roy - JonesTrading - Analyst : Good morning everyone and thank you again for organizing this event. One question on the enrollment criteria, given the co-infection rates of the other patients, what do you expect the screen failure rate to be? And the second one is dovetailing on the prior question. The life cycle of the virus, does integrated DNA turn into cccDNA also? And if ARCUS system has activity against the integrated DNA also.

Question: Andrea Newkirk - Goldman Sachs - Analyst : Hi everyone. Thanks for taking another question from us. I was just wondering if you could speak on the considerations that drive the decision to re-dose within this study. Thanks so much.